import type { BlogPostMeta } from "@/lib/blog/types"
import {
  H2,
  H3,
  P,
  Lead,
  UL,
  OL,
  LI,
  Strong,
  Em,
  BQ,
  Callout,
  KeyTakeaways,
} from "@/components/blog/prose"

export const meta: BlogPostMeta = {
  slug: "fertility-clinic-marketing-compliance",
  title:
    "Fertility Clinic Marketing Compliance: IVF Success Rate Claims, SART Disclosure, and the Specific Rules That Apply",
  description:
    "Fertility and IVF clinic marketing operates under SART success rate reporting rules, specific FTC outcome-claim scrutiny, and considerations around LGBTQ+ family building and donor/surrogacy services.",
  excerpt:
    "Fertility clinic marketing faces some of the most specific success-rate reporting rules in healthcare. Here's the full framework for IVF, egg freezing, donor services, and emerging fertility-tech marketing.",
  date: "2026-04-22",
  readingMinutes: 9,
  keywords: [
    "fertility clinic marketing compliance",
    "IVF success rate advertising",
    "SART reporting rules",
    "egg freezing marketing",
    "fertility clinic FTC",
  ],
  tags: ["Fertility", "Specialty playbook"],
  author: { name: "RegenCompliance Editorial", role: "FDA/FTC compliance desk" },
  heroLabel: "Specialty playbook",
}

export default function Body() {
  return (
    <>
      <Lead>
        Fertility and IVF clinic marketing operates under some of
        the most specific success-rate reporting rules in healthcare,
        shaped by the Fertility Clinic Success Rate and Certification
        Act of 1992 and ongoing SART (Society for Assisted
        Reproductive Technology) reporting. Add FTC scrutiny of
        outcome claims, state-specific rules on fertility advertising,
        and the emerging complexity of donor/surrogacy marketing,
        and fertility clinic marketing has a compliance profile
        unlike most other specialties.
      </Lead>

      <H2 id="success-rate-rules">IVF success rate reporting rules</H2>
      <P>
        The Fertility Clinic Success Rate and Certification Act
        requires IVF clinics to report success rates to the CDC, which
        publishes national data. SART publishes its own member clinic
        data. Marketing considerations:
      </P>
      <UL>
        <LI>
          Clinics should accurately represent their success rates
          consistent with SART/CDC reporting.
        </LI>
        <LI>
          Success rate presentations should specify denominators
          (per cycle started, per transfer, per retrieval, live birth
          rate, pregnancy rate).
        </LI>
        <LI>
          Comparing clinic rates without appropriate context
          (patient age distribution, case complexity) creates
          misleading comparison issues.
        </LI>
        <LI>
          Historical rates require time-period disclosure.
        </LI>
      </UL>

      <H2 id="problematic-patterns">Problematic marketing patterns</H2>

      <H3>Pattern 1: Cherry-picked success rates</H3>
      <P>
        Selecting the most favorable age group or cycle type to
        advertise without clear disclosure of what specific rate
        you&rsquo;re presenting creates deceptive-marketing exposure.
        The clinic may have legitimate reasons for specific patient
        populations but marketing needs context.
      </P>

      <H3>Pattern 2: Outcome guarantees</H3>
      <P>
        &ldquo;Money-back if no baby&rdquo; programs exist but face
        careful regulatory review. Their compliance depends on clear
        disclosure of exclusions, eligibility, and refund mechanics.
        Broad outcome guarantees without this framing create
        exposure.
      </P>

      <H3>Pattern 3: &ldquo;Leading&rdquo; or &ldquo;best&rdquo; claims</H3>
      <P>
        Comparative claims between fertility clinics need
        substantiation. Age-adjusted outcome comparisons are complex;
        &ldquo;highest success rate&rdquo; claims are typically
        unsubstantiable without specific evidence.
      </P>

      <H3>Pattern 4: Egg freezing marketing</H3>
      <P>
        Egg freezing marketing faces specific considerations:
      </P>
      <UL>
        <LI>
          Future-pregnancy outcome marketing based on egg freezing
          is speculative &mdash; actual outcomes depend on future
          uses that have not yet occurred.
        </LI>
        <LI>
          &ldquo;Insurance policy&rdquo; framing of egg freezing
          has been criticized by FTC-adjacent commentary.
        </LI>
        <LI>
          Employer-benefit egg-freezing marketing has its own
          specific framing considerations.
        </LI>
      </UL>

      <H3>Pattern 5: Donor gamete and embryo marketing</H3>
      <P>
        Donor marketing (egg donors, sperm donors, embryo donation)
        has specific rules:
      </P>
      <UL>
        <LI>
          Donor recruitment marketing has FDA and state
          considerations.
        </LI>
        <LI>
          Matching service marketing faces consumer protection
          scrutiny.
        </LI>
        <LI>
          Outcome claims for specific donor categories need
          substantiation.
        </LI>
      </UL>

      <H3>Pattern 6: Gestational surrogacy</H3>
      <P>
        Surrogacy marketing varies by state legality and has
        specific federal and state rules beyond standard healthcare
        marketing. International surrogacy marketing adds jurisdiction
        complexity.
      </P>

      <H3>Pattern 7: LGBTQ+ family-building marketing</H3>
      <P>
        Marketing to LGBTQ+ patients requires accurate description
        of services, costs, and legal considerations. Varied state
        laws on parental rights in assisted reproduction affect
        what outcomes are achievable in specific states.
      </P>

      <H2 id="emerging-issues">Emerging fertility-tech marketing</H2>
      <UL>
        <LI>
          <Strong>PGT (preimplantation genetic testing).</Strong>
          Specific clinical-utility claims require substantiation;
          expanded indication marketing has drawn specific
          attention.
        </LI>
        <LI>
          <Strong>Mitochondrial replacement therapy.</Strong>
          Marketing for non-FDA-approved procedures.
        </LI>
        <LI>
          <Strong>Fertility-awareness apps and wearables.</Strong>
          Some are FDA-regulated; marketing should reflect accurate
          regulatory status.
        </LI>
        <LI>
          <Strong>AI-assisted embryo selection.</Strong> Claims about
          improved outcomes need substantiation.
        </LI>
      </UL>

      <H2 id="financing-pricing">Financing and pricing marketing</H2>
      <P>
        IVF pricing marketing is a specific consumer-protection
        focus:
      </P>
      <UL>
        <LI>
          &ldquo;$X per cycle&rdquo; marketing needs clear
          disclosure of medications, monitoring, facility fees, and
          other costs.
        </LI>
        <LI>
          Package programs (multi-cycle, shared-risk) have specific
          disclosure requirements.
        </LI>
        <LI>
          Financing partnership disclosure for loan programs.
        </LI>
        <LI>
          Insurance-coverage claims need accuracy about what
          insurance typically covers vs what&rsquo;s out-of-pocket.
        </LI>
      </UL>

      <H2 id="compliant-framework">Compliant fertility marketing framework</H2>
      <OL>
        <LI>
          <Strong>Accurate success rate presentation.</Strong> Cite
          specific SART-reported rates with appropriate age and
          denominator context.
        </LI>
        <LI>
          <Strong>Service-first marketing.</Strong> Describe the
          clinical approach, patient experience, and team rather
          than leading with outcome claims.
        </LI>
        <LI>
          <Strong>Honest evidence framing.</Strong> Success depends
          on many factors; marketing that acknowledges this is both
          honest and compliant.
        </LI>
        <LI>
          <Strong>Financial transparency.</Strong> Clear disclosure
          of what pricing includes and what typical total costs
          look like.
        </LI>
        <LI>
          <Strong>Appropriate emotional tone.</Strong> Fertility is
          emotionally heightened; marketing should respect that
          without exploitation.
        </LI>
        <LI>
          <Strong>Inclusive and accurate family-building framing.</Strong>
          LGBTQ+, single-parent, and non-traditional family building
          marketing should be accurate about what&rsquo;s achievable.
        </LI>
      </OL>

      <H2 id="faqs">Frequently asked questions</H2>

      <H3>Can I market our clinic as having higher success rates than average?</H3>
      <P>
        With accurate substantiation and appropriate context. Cite
        specific SART-reported rates with the specific metric and
        age-group. Avoid &ldquo;higher than average&rdquo; without
        specific benchmark citation.
      </P>

      <H3>How should I handle patient stories and testimonials?</H3>
      <P>
        With HIPAA authorization and typical-experience framing.
        Fertility success stories are emotionally powerful marketing
        but carry disease-treatment claim exposure if tied to
        specific outcome promises.
      </P>

      <H3>What about shared-risk and money-back programs?</H3>
      <P>
        These programs can be structured compliantly but need
        specific disclosure of eligibility, exclusions, refund
        mechanics, and actual outcomes. They&rsquo;ve drawn state
        consumer protection attention when disclosure is inadequate.
      </P>

      <H3>Can I market to specific age groups?</H3>
      <P>
        Yes, with accuracy. Age-specific fertility marketing should
        reflect accurate age-related outcome considerations. Urgent
        framing of fertility decline should be supported by accurate
        clinical context, not scare-based marketing.
      </P>

      <H3>What about international patient marketing?</H3>
      <P>
        International patient marketing adds medical tourism
        considerations on top of fertility-specific rules. State
        licensure requirements for clinical care remain regardless
        of patient origin.
      </P>

      <H3>Do I need to report specific outcome data by request?</H3>
      <P>
        SART reporting is the primary regulatory framework. Patient
        requests for specific outcome data should be handled
        consistent with your regular clinical communication
        practices.
      </P>

      <KeyTakeaways
        items={[
          "Fertility clinic success rate reporting is federally regulated (SART/CDC reporting); marketing should reflect those frameworks accurately.",
          "Cherry-picked success rates without context, outcome guarantees without clear structure, and superlative claims without substantiation are common enforcement patterns.",
          "Egg freezing marketing as an 'insurance policy' has drawn specific criticism; honest framing of speculative future outcomes is compliance-safer.",
          "Donor and surrogacy marketing add jurisdiction-specific rules on top of standard fertility marketing.",
          "Financial transparency in IVF pricing is a growing state AG focus; unclear disclosure of total costs creates exposure.",
        ]}
      />
    </>
  )
}
